Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

(2015) Mélanie Drolet et al.   LANCET INFECTIOUS DISEASES

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

(2015) Elmar A. Joura et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial

(2015) Matti Lehtinen et al.   VACCINE

Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens

(2014) J. E. Tota et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination

(2013) J. E. Tota et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

(2013) A. Szarewski et al.   JOURNAL OF INFECTIOUS DISEASES

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

(2013) D. Mesher et al.   VACCINE

Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination

(2012) Johanna Palmroth et al.   INTERNATIONAL JOURNAL OF CANCER

Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction

(2012) J. A. Kahn et al.   PEDIATRICS

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

(2012) Beatriz Serrano et al.   Infectious Agents and Cancer

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Serotype replacement in disease after pneumococcal vaccination

(2011) Daniel M Weinberger et al.   LANCET

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies

(2011) Joseph E. Tota et al.   PREVENTIVE MEDICINE

Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica

(2011) R. Herrero et al.   Cancer Discovery

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

(2010) Silvia de Sanjose et al.   LANCET ONCOLOGY

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

(2009) Cosette M. Wheeler et al.   JOURNAL OF INFECTIOUS DISEASES

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

(2009) Mark Schiffman et al.   Infectious Agents and Cancer

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

(2008) Rolando Herrero et al.   VACCINE